Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Oct 2, 2019

Keywords

ClinConnect Summary

This clinical trial, called the AtTRIBut study, is exploring how radiation therapy interacts with new cancer treatments known as molecular agents, like immunotherapy. Many cancer patients receive radiation therapy to help manage their symptoms, especially when their cancer has spread to other parts of the body. As more patients start receiving both radiation and these new therapies, it's important to understand how they work together and any side effects that may arise.

To participate in this trial, you need to be at least 18 years old, have a confirmed diagnosis of cancer, and be currently receiving molecular therapy while also needing radiation treatment. Participants will be part of a registry to help gather information about their experiences and any side effects they may encounter. This study is actively recruiting participants, and it aims to improve our understanding of how these treatments can affect patients, ultimately leading to better care and support for those undergoing cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Consent to be part of the AtTRIBut registry
• • Prior histological diagnosis of primary cancer.
• • If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis
• • Age\> 18 years
• • Receiving a molecular therapy
• • Indicated to receive radiotherapy
• • Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.
• Exclusion Criteria:
• • • Refusal or inability to receive radiotherapy